Usefulness of the drug allergy passport in the drug allergy management.
allergy
drug allergy passport
drug hypersensitivity reactions
Journal
Postepy dermatologii i alergologii
ISSN: 1642-395X
Titre abrégé: Postepy Dermatol Alergol
Pays: Poland
ID NLM: 101168357
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
30
10
2019
accepted:
14
01
2020
entrez:
11
8
2021
pubmed:
12
8
2021
medline:
12
8
2021
Statut:
ppublish
Résumé
Nowadays, the number of people with drug hypersensitivity has been increasing and it has become a major problem for the healthcare system. Unfortunately, not everyone is aware of which medications they can safely use. To assess the suitability of a drug allergy passport in patients with drug hypersensitivity in order to increase knowledge about medicines that can be safely used. The study was conducted in 54 hospitalized patients with confirmed hypersensitivity to drugs by issuing a drug passport at discharge. The study was carried out with the questionnaire method. The questionnaire was conducted by phone 3, 6 and 12 months after the patients received the drug passport. Fifty-eight people were contacted by phone. The survey was conducted in 54 people (42 women (77%), mean age: 48, range: 19-71), which gives a response rate of 98%. The application of the drug allergy passport by patients increased with time and the number of patients who did not use their passport decreased. With time, patients showed the drug allergy passport to a larger number of doctors, most often to general practitioners and dentists. In the following months, the number of doctors who followed passport recommendations and patients who adhered to the passport recommendations increased. The analysis of drug allergy passport shows that patients are better informed about medicines they can use and have a greater sense of security. By showing the passport to specialists, they choose the safest and adequate treatment.
Identifiants
pubmed: 34377124
doi: 10.5114/ada.2021.107930
pii: 107930
pmc: PMC8330863
doi:
Types de publication
Journal Article
Langues
eng
Pagination
433-439Informations de copyright
Copyright: © 2021 Termedia Sp. z o. o.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Pharm World Sci. 2009 Aug;31(4):464-472
pubmed: 19412703
Drug Saf. 2015 May;38(5):437-53
pubmed: 25822400
J Investig Allergol Clin Immunol. 2017;27(1):32-39
pubmed: 28211343
BMC Health Serv Res. 2016 Aug 09;16(a):363
pubmed: 27507250
Allergy. 2016 Sep;71(9):1305-13
pubmed: 26970431
BMJ Case Rep. 2015 Feb 25;2015:
pubmed: 25716039
Allergy. 2017 Jul;72(7):1123-1128
pubmed: 28122131
Lancet. 2000 Oct 7;356(9237):1255-9
pubmed: 11072960
J Allergy Clin Immunol. 2011 Jan;127(1):284-5
pubmed: 21211662
Allergy. 2014 Apr;69(4):420-37
pubmed: 24697291
Allergy. 2016 Nov;71(11):1533-1539
pubmed: 27145347
An Pediatr (Barc). 2016 Mar;84(3):148-53
pubmed: 26195066
J Investig Allergol Clin Immunol. 2016;26(2):100-5
pubmed: 27164625
J Allergy Clin Immunol. 2004 May;113(5):832-6
pubmed: 15131563
Allergy. 2002 Jan;57(1):45-51
pubmed: 11991289
Clin Transl Allergy. 2018 May 10;8:16
pubmed: 29760877